Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo losartan Clear all
Completed Phase 2 Interventional Results available

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

NCT01150461
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
losartan, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Early Phase 1 Interventional Results available

Losartan for Improved Vascular Endothelial Function After Preeclampsia

NCT04632589
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Losartan Potassium, Placebo
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

NCT01384591
View directory record Official record
Conditions
Aging
Interventions
N-acetylcysteine, Losartan, Placebo losartan, Placebo N-acetylcysteine
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 17, 2026, 6:51 AM EDT
Recruiting Phase 2 Interventional

Losartan to Improve Outcomes After Multi-ligament Knee Injury

NCT06933706
View directory record Official record
Conditions
Multi-ligament Knee Injury
Interventions
losartan 25 mg, Placebo capsule
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Lexington, Kentucky • Bethesda, Maryland • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 17, 2026, 6:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

NCT06108063
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
Losartan, Placebo - Losartan
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 17, 2026, 6:51 AM EDT
Recruiting Phase 2 Interventional

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

NCT06364176
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

Olmesartan Comparison to Losartan in Hypertensive Subjects

NCT00949884
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Placebo, losartan potassium
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • Harbor City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 17, 2026, 6:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Losartan to Improve Hip Microfracture

NCT04212650
View directory record Official record
Conditions
Hip Osteoarthritis, Hip Impingement Syndrome, Cartilage Damage, Fibrosis
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 17, 2026, 6:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains

NCT02263729
View directory record Official record
Conditions
Hamstring Injury
Interventions
Losartan, Placebo
Drug
Lead sponsor
James J. Irrgang
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

NCT00734630
View directory record Official record
Conditions
Hypertension
Interventions
nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
75
States / cities
Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 17, 2026, 6:51 AM EDT
Not listed Phase 1Phase 2 Interventional

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

NCT04815902
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Fisetin, Losartan, Placebo - Losartan, Placebo Fisetin
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
40 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 2 Interventional

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

NCT01398423
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Active Control, INV-144
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Garden Grove, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 17, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional Results available

Losartan for the Treatment of Pediatric NAFLD

NCT03467217
View directory record Official record
Conditions
NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Losartan potassium, Placebo losartan capsule
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 17, 2026, 6:51 AM EDT
Terminated Phase 4 Interventional

Effect of Sulodexide in Overt Diabetic Nephropathy

NCT00130312
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 17, 2026, 6:51 AM EDT
Not yet recruiting Phase 4 Interventional

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

NCT07135687
View directory record Official record
Conditions
ACL Injury, ACL Reconstruction, Scar Formation
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Losartan in the Treatment of NAFLD in Children

NCT01913470
View directory record Official record
Conditions
NAFLD
Interventions
Losartan
Drug
Lead sponsor
Miriam Vos, MD
Other
Eligibility
11 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 17, 2026, 6:51 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

NCT05025956
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 17, 2026, 6:51 AM EDT
Recruiting Phase 4 Interventional

Secondhand Tobacco Smoke and Cardiovascular Disease

NCT04715568
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

Angiotensin II Blockade for Chronic Allograft Nephropathy

NCT00067990
View directory record Official record
Conditions
Kidney Disease, Proteinuria
Interventions
Losartan 100mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 17, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 17, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional Results available

Losartan and Inflammation in Cystic Fibrosis

NCT03206788
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Losartan, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

NCT02676466
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo)
Dietary Supplement · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
70 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 17, 2026, 6:51 AM EDT
Terminated Phase 2Phase 3 Interventional

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

NCT04328012
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Losartan, Placebo
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 17, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Muscle Strength Maintenance in Older Adults

NCT01989793
View directory record Official record
Conditions
Sarcopenia
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
70 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 17, 2026, 6:51 AM EDT